Sellas Life Sciences shares gained momentum on August 27, 2026. Cathie Wood’s ARK Investment Management highlighted the growth potential of the personalized cancer-vaccine market. This commentary drew investor attention to Sellas’s lead candidate, galinpepimut-S (GPS). GPS is a cancer vaccine designed to target the WT1 protein.
ARK’s podcast projected a positive outlook for custom cancer treatments. The firm specifically cited the Merck and Moderna collaboration on Intsmeran as a potentially life-saving therapy. This bullish sentiment from a high-profile investor increased interest in companies active within the sector. Sellas is currently evaluating GPS in the Phase 3 REGAL trial for acute myeloid leukemia (AML) maintenance therapy.